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Abstract
Background: In cervical tumours the integration of human papilloma viruses (HPV) transcripts
often results in the generation of transcripts that consist of hybrids of viral and cellular sequences.
Mapping data using a variety of techniques has demonstrated that HPV integration occurred
without obvious specificity into human genome. However, these techniques could not demonstrate
whether integration resulted in the generation of transcripts encoding viral or viral-cellular
sequences. The aim of this work was to map the integration sites of HPV DNA and to analyse the
adjacent cellular sequences.
Methods: Amplification of the INTs was done by the APOT technique. The APOT products were
sequenced according to standard protocols. The analysis of the sequences was performed using
BLASTN program and public databases. To localise the INTs PCR-based screening of GeneBridge4-
RH-panel was used.
Results: Twelve cellular sequences adjacent to integrated HPV16 (INT markers) expressed in
squamous cell cervical carcinomas were isolated. For 11 INT markers homologous human genomic
sequences were readily identified and 9 of these showed significant homologies to known genes/
ESTs. Using the known locations of homologous cDNAs and the RH-mapping techniques, mapping
studies showed that the INTs are distributed among different human chromosomes for each
tumour sample and are located in regions with the high levels of expression.
Conclusions: Integration of HPV genomes occurs into the different human chromosomes but into
regions that contain highly transcribed genes. One interpretation of these studies is that integration
of HPV occurs into decondensed regions, which are more accessible for integration of foreign
DNA.
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Background
Cervical cancer is the second most common cause of can-
cer related mortality in women world-wide. Most cervical
cancers are squamous cell carcinomas that develop
through a distinct pattern of morphological progression.
Cervical tumours are associated at a high frequency with
infection by human papilloma viruses (HPV) and se-
quences of the so-called high risk HPV (types 16 and 18
and related) are detected in nearly every tumour examined
[1]. Viral DNA persists in tumour cells in episomal and/or
integrative forms with the retention of the two of viral
transforming genes (E6 and E7) in all tumours analysed.
The expression of viral sequences is controlled by se-
quences within the upstream regulatory region (URR) that
is located upstream of the E6 gene. Viral transcripts in-
clude a variety of spliced RNA. In cases where the episom-
al form of HPV predominates, the full expression of E6
and E7 genes occurs (few splicing forms), while in the case
of integrative form – the expression of cellular sequences
downstream to 3' of viral sequences also can be detected
in the form of fused viral-cellular RNAs [2]. It is also pos-
sible that, in some cases, after integration viral sequences
become "silent" [3,4].
Analysis of integration sites based on different techniques
and their mapping in the human genome revealed that
DNA integration of different HPV types occurred in differ-
ent chromosomal sites without visible specificity [5–12].
It was demonstrated that in some case sites of viral ge-
nome integration mapped to regions of human genome
that often underwent chromosomal rearrangements and
deletions. In other cases HPV integration sites were
mapped to so called fragile sites, or in regions where genes
that are directly or indirectly involved in the control of cell
proliferation have been localised. Not all of these meth-
ods give precise and adequate data and in addition they
can not discriminate between "silent" and integrated viral
DNA. Furthermore, in many cases these methods do not
allow precise physical mapping of integrative viral se-
quences. The use of the so-called APOT techniques have
greatly simplified the analysis of expressed integration
sites and allowed characterisation of a large number of in-
tegration sites through analysis of expressed joint viral-
cellular sequences. The major conclusion from these stud-
ies was that integration is non-specific [12].
Although analysis of many integration sites has already
been described, a detailed examination using different
techniques seemed important, since it provides additional
information concerning the interaction of viral and host
genomes and the role of this process in genetic program of
cancer cell.
The primary aim of this work was the physical mapping of
the integration sites of HPV 16 DNA in chromosomes of
human cervical squamous cell carcinomas by isolation of
integration sites by APOT technology. This was followed
by mapping of the expressed virus-cellular sequences gen-
erated by integration using PCR screening of a panel of ra-
diation hybrids of somatic cells as well as database
analysis of cellular sequences located adjacent to integra-
tion sites.
Methods
Original materials
All tumour samples were collected during surgery in the
clinics of Cancer Research Centre (Moscow) and were
kept frozen in liquid nitrogen. DNA and RNA isolation
and HPV typing were performed according to techniques
described earlier [13]. Only squamous cell carcinomas
containing HPV 16 sequences were analysed.
Amplification of fusion transcripts
Human genomic sequences adjacent to integrated HPV 16
DNA from squamous cell cervical carcinomas have been
isolated with the use of the APOT technique [2] based on
reverse transcription with further two step amplification
of RT-product [3,2] (HPV integration sites – INT). This
technique was described earlier in detail [2,3].
Briefly reverse transcription was performed using an
adapter linked oligo(dT)-primer [14] followed by semi-
nested PCR using E7-specific 5' primed primers and spe-
cific oligo(dT)/adapter primers (3' primed) [2,12,3]. PCR
products were transferred onto nylon membranes and hy-
bridised with HPV E7 and E4 specific probes to discrimi-
nate episomal from integration derived transcripts. PCR
products containing integration sites were excised from
the gel and extracted using the QIAGEN Gel extraction kit
(Qiagen, Hilden, Germany). Sequencing reactions were
performed using Big-Dye terminator DNA-sequencing Kit
(Perkin-Elmer, Boston, USA) and an ABI Prism 310 Ge-
netic analyzer (Applied Biosystems, Foster City, USA). Se-
quencing results were analysed using BLASTN-program
provided by the National Cancer Insitute. The sequences
of the 12 studied INTs were submitted in EMBL Database
(AccN: AJ431608 – INT254, AJ431609 – INT259,
A431610 – INT431, AJ431611 – INT407, AJ631612 –
INT290, AJ431614 – INT505, AJ431615 – INT477,
AJ431616 – INT467, AJ431617 – INT466, AJ431618 –
INT421, AJ431619 – INT475, AJ431620 – INT423).
Physical mapping of HPV 16 DNA on human chromosomes
To localise INTs, PCR-based screening of a somatic cell ra-
diation hybrid (human/hamster) GeneBridge4-RH-panel
(Research Genetics Inc., USA) was applied as described
earlier [15].
PCR was performed in 12.5 l reactions, using a PTC-
100™ thermocycler (MJ Research Inc., USA). Some modi-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/24
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fications were introduced, including the "hot start" tech-
nique, as recommended in the instructions for Maxi-
Taq™, manufactured by Biokom Inc. (Russia). The
amount of DNA per tube was 8–10 ng. The nucleotide se-
quences of the primers used in these studies are presented
in Table 1. Conditions for annealing, priming, and other
parameters were optimised using total human and ham-
ster DNAs (Table 1). The analysis of PCR products using
agarose and polyacrylamide gels was performed following
standard protocols.
The results of PCR screening of the RH-panel were ana-
lysed with RHMAPPER through the server of the Whitehe-
ad Institute/MIT Centre for Genome Research  [http://
carbon.wi.mit.edu:8000/cgi-bin/contig/rhmapper.pl]. To
reconcile these data with previously reported information
regarding maps of the chromosome, three additional
sources were used  [http://www.ncbi.nlm.nih.gov/];  [ht-
tp://www.stanford.edu/RH/];  [http://www.tigr.org/].
Search for sequences homologous to cellular markers of 
DNA HPV 16 integration sites
Search for homologies was carried out using the BLASTN
program  [http://www.ncbi.nlm.nih.gov/BLAST/], and da-
tabases GeneBank and EMBL. This search was done as fol-
lows:
a) search for homologies of INT sequences with human
genomic sequences in HGMT database;
b) selection of drawling genomic sequences, which in-
clude sequences homologous to INT markers;
c) selection of genomic fragments, that flank INT marker
from 5' and 3' ends, as long as 2000 nucleotides from
both ends;
d) search for homologies of genomic DNA fragments se-
lected with genes and cDNAs by use of well known data-
bases (GeneBank and EMBL).
Information concerning proteins, encoded by genes that
are homologous to DNA HPV 16 integration sites and are
mapped in their site of localisation, was obtained from
OMIM database  [http:///www.ncbi.nlm.nih.gov/] and
LocusLink  [http://www.ncbi.nlm.nih.gov/LocusLink/].
The data on RH-mapping are presented in March 2001
and the data on mapping of markers on chromosomes
and genomic contigs – to September 2001. Information
about search of homologies corresponds to the public da-
tabases for January 2002.
Results
Detection of DNA HPV 16 integration sites
APOT technique was used to isolate human genomic se-
quences adjacent to integrated HPV 16 DNA (HPV inte-
gration sites – INTs) expressed in squamous cell cervical
carcinomas. This technique is based on a modification of
RT-PCR methods using specific primers, one of which was
localised in E7 region of viral genome and a second one
which contains specific adapter sequences joined with ol-
igo(dT) [2,3]. As a result we generated fusion transcripts
that encompassed parts of the human genomic DNA.
Some of the transcripts may be spliced into non-coding
sequences within the 3' untranslated part of the respective
genomic mRNAs and others – into intronic regions close
to the transcription initiation site of the respective gene as
was recently shown by Wentzensen et al. [12]. We have
not analysed in detail these types of fusion transcripts, but
in the all cases our methods allowed discrimination be-
tween expressed episomal and integrative forms of HPV
DNA.
Table 1: Primers and PCR conditions
Marker Primers 3'-5' Annealing TC / time, sec Amplification product, bp
INT254 F: CTTTCAGCAAAGGATGTCATTG
 R: GCAAGGCTTATTAAGCTTCAGC
57C / 50 203
INT259 F: ATCTACAGACAGCATGGTACGG
 R: TCAGAACACAACAAAAGGATGC
60C / 45 107
INT431 F: TCCAAAAAAATGAGGCAATCTC
 R: GGACTGAGGGAATAAACGACAC
60C / 50 101
INT407 F: AGCAGGAGATGACAAGATGTTG
 R: CACAAGTAGCTGAGACCACAGG
55C / 35 103
INT290 F: AAGTTCCACCATTCAAGACCAG
 R: TCATGATATCCTTGGTGTCCTG
55,5C / 45 215BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/24
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Twelve INT sequences have been characterised from dif-
ferent individual squamous cell cervical carcinomas. The
length of the cellular sequences containing polyA tails and
fused to viral sequences varied from 140 to 450 nucle-
otides. The sequences were submitted in EMBL Database
(see Methods section for AccN) and used for searching ho-
mologies to human genomic sequences, genes and ESTs.
Corresponding primers were created to these cellular se-
quences at integration sites and were used for screening of
RH-panel of somatic cell hybrids (Table 1).
Analysis of nucleotide sequences homologous to integra-
tion sites
Searches for human nucleotide sequences that were ho-
mologous to INT markers were carried out using BLASTN
program and public databases as described in Materials
and Methods. Homologies greater than 90% for sequenc-
es not less than 100 nucleotides in size were considered
significant.
Homologies with cDNA clones were found for only 5 of
the 12 analysed INT clones and this may in part be due to
the relatively small size of the markers examined (150–
350 base pairs). Homologous genomic sequences were
found for 11 INT markers (Table 2, see Additional file 1).
This allowed us to extend significantly the search for EST
homologies to longer cellular sequences (up to 2.000 bp)
that flanked integrated viral genome. For almost all mark-
ers (excluding INT431, INT254 and INT407) homologies
with cDNAs that are highly similar to cDNAs for known
genes or with non-identified cDNAs were found.
In the cases where homology with the same gene or EST
was detected both with INT markers and with adjacent
cellular sequences, one may conclude that (markers
INT290, INT505, INT466 and INT423) HPV DNA had in-
tegrated into a human gene in this cervical carcinoma. The
integration of viral DNA occurred into the terminal exon
of GLS gene and provides a clear example of integration
into an actively transcribed gene (marker INT423).
An integration site marked as INT466 is of special interest
as it is highly likely that viral DNA is incorporated into the
exon 5 of the interferon/beta receptor like gene
(LOC152028). One part of the marker is homologous to
the exon 5 and the other part is homologous to the exon
6 of this gene.
Marker INT290 was found to be homologous to two
genes: to the WASF2 gene and the gene for the protein
similar to WASF2 protein (LOC158537) located on the
different chromosomes (1p36.11-34.3 and Xp11.3 ac-
cordingly).
The corresponding human genomic sequence was not
found for one of the markers (INT467) although a high
level of homology was found with a cDNA similar to
mRNA of multicopy gene 40S ribosomal protein S27
(MPS1), which is localised on several human chromo-
somes (1, 2, 3, 4, 5, 6, 7, 11, 12, 15, 18, 19).
In four cases homologies were not found between INT
markers (INT259, INT477, INT421 and INT475) and any
genes or ESTs. But the sequences flanking these markers
from 5'- or 3'-ends were homologous to ESTs (Table 2 see
Additional file 1). For three INT markers (INT254,
INT407 and INT431) and their adjacent cellular sequenc-
es homologies to genes or ESTs were not found. For this
reason, the physical locations of these markers were deter-
mined using RH-mapping. All variants of cDNAs that are
homologues to INT markers and flanking genomic se-
quences are present at high levels in expression databases
(10–50 clones) indicating a high level of expression. For
this study, clones were obtained from different human
normal organs and tissues, as well as from different
pathologies (including tumours).
RH-mapping of INT markers
The known locations of the cDNAs and human genomic
sequences identified above allowed us to localise nine INT
markers, which are highly homologous to these cDNAs
(Table 2, see Additional file 1). Two INT markers were
found to have multiple chromosomal localisation
(INT467 and INT290). In seven cases the locations of the
integration sites are specific for each tumour and the
markers are present as a single copy in one of the chromo-
somes. RH-mapping has been used to localise INT254,
INT431 and INT407, for which there were no homologies
to genes or ESTs and INT290. In addition, the location of
the INT259 was also determined using RH-mapping be-
cause the lengths of the homologous sequences were too
short (104 bp and 59 bp).
Altogether five INT markers were localised on the radia-
tion hybrid map of Whitehead Institute (WI-RH-Map) as
a result of our screening (Table 3, see Additional file 2). To
allow for a convenient comparison of our data with the
public databases, we converted the INT marker positions
in Whitehead Institute RH-map (WI-RH-Map) into the
GeneMap99-GB4 (GM99-GB4) (Table 3, see Additional
file 2). This recalculation should not generate any errors
because the physical locations for the majority of frame-
work markers are known for both RH-maps. This proce-
dure allows for a more complete analysis of information
from the public databases. Physical intervals and subloci
of chromosomes in which INT sequences are located were
determined. YAC-contigs and genomic contigs, to which
mapped markers belong, were identified and the physical
localisation on chromosomes was defined (Table 3, seeBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/24
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Additional file 2). The physical locations of five INT mark-
ers mapped by us were in a good agreement with the loca-
tions of the corresponding contigs of human genomic
sequences. The locations of these integration sites are also
specific for each tumour and all of the markers are present
as a single copy in one of the chromosomes including
INT290 located on Xp11.21. The maps of chromosomes
in which the sites of INT markers and genes located in the
same regions of the chromosomes are indicated are pre-
sented on Fig. 1.
The analysed HPV integration sites were found to be locat-
ed on different human chromosomes and no obvious de-
gree of specificity of the integration sites is present.
Nevertheless, it is interesting to note that one of INT sites
(INT431) mapped in the region 13q14-q21 that is saturat-
Figure 1
Locations of INT markers on human chromosomes (RH-mapping data). Bold marked INT markers. In Italics marked genes that
are adjacent to INT markers: similar to WASF2 – Wiskott-Aldrich syndrome gene; ZNF174 – zinc finger protein 174; NUMB –
numb homologue (Drosophila) (neurone grow factor); LTBP2 – latent transforming growth factor beta binding protein 2; PGF –
placental growth factor; EDG2 – endothelial differentiation, lysophosphatidic acid G-protein-coupled receptor, 2; PCDH8 – pro-
tocadherin 8; CTNNAL1 – catenin (cadherin-associated protein), alpha-like 1; TCRA – T cell receptor alpha locus; CKAP2, LEU2 –
tumour-suppressers genes.BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/24
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ed with tumour suppressers genes such as CKAP2, LEU1
and CLL-4[16]. Some other genes, that are located around
other INT positions, may also belong to the group of tu-
mour suppressers. The genes that participate in the proc-
esses of development and differentiation of tissue
(NUMB, LTBP2, PGF andEDG2), genes encoding for sig-
nal proteins (similar to WASF2, ZNF 174), and proteins of
cytoskeleton (PCH8, CTNNAL1) are also present in these
loci (Fig. 1).
Discussion
The analysis of the physical locations of integrated HPV
16 DNA expressed in squamous cell carcinomas of cervix
using RH-technology and examination of the cellular se-
quences adjacent to the INTs allows us to confirm previ-
ous studies indicating that viral integration sites are
randomly distributed in human genome [11,12]. Integra-
tion of viral DNA occurs into different regions of chromo-
somes and does not seem to be site-specific. Interestingly,
many important genes participating in processes of cellu-
lar growth and differentiation were found to be located
around these sites of viral integration (Fig. 1). These in-
cluded three markers (INT254, INT431 and INT505) that
are present in the area of known fragile sites and mapped
to 14q23 (INT254 – 14q23.2), 13q21.2 (INT431 –
13q21.23) and 10q23.3 or 10q24.2 (INT505 –
10q23.32).
Analysis of ESTs homologous to INT sequences allowed
us to obtain additional information about the putative
genes into which viral DNA is incorporated. As a rule
these are sequences are similar to genes encoding for pro-
teins that are important for cell division, differentiation
and cell viability. For instance membrane protein myofer-
lin (gene MYOF – marker INT505) participates in the de-
velopment and differentiation of muscle tissue [[17];
OMIM: 604603]. Ribosomal protein S27 (marker
INT467) contains a predicted zinc finger domain of the
C4 type and can bind to DNA [[18]; OMIM: 603702]. The
protein responsible for Wiskott-Aldrich syndrome (mR-
NA similar to WASF2 gene – marker INT290) belongs to
the family of GTP-ases that transduce signal to actin from
cytoskeleton. It was shown for WASF2 gene, that its ex-
pression induces the abnormal accumulation of actin
[[19]; OMIM: 605875]. Interferon (marker INT466) be-
longs to the protein factors that are associated with cellu-
lar response to viral infections [OMIM: 107450].
Glutaminase (GLS – marker INT423) participate in the
synthesis of glutaminate, which appear to be a neuro-
transmitter [[20,21]; OMIM: 138280]. Nuclear gene
RTN4IP1 (marker INT475) encoded reticulon 4 interact-
ing protein 1, which function is unknown [LocusLink ID:
84816].
All these data are in a good correlation with other recently
published studies [10,11]. The conclusions of these addi-
tional studies, which used other techniques of analysis of
integration sites, indicated that the sites of integration
may be associated with fragile sites as well as a different
spectrum of genes or EST sequences. It is also necessary to
point out that we as well as Wentzenzen et al. [12] ana-
lysed only expressed sequences from integration sites in
which cellular sequences localised downstream to viral se-
quences.
These data address the question about the possible role of
HPV DNA integration in tumour development. Among
cervical tumours around 50% contain viral DNA in episo-
mal form [3,22,23]. This may indicate that persistence of
viral transforming genes E6 and E7 products that inacti-
vate products of tumour-suppresser genes p53 and Rb105
and some of cyclins [24–26] is important and that integra-
tion does not play a crucial role in cervical tumour pro-
gression.
In our study we also demonstrated that cDNAs, that are
homologous to INT markers, have high levels of expres-
sion in cells. These data were also confirmed by our addi-
tional experiments not presented in this manuscript
analysing amplified sequences transcribed from total RNA
isolated from different normal and tumour cells of epithe-
lial origin. This suggests that the regions with actively tran-
scribed genes are in decondensed form, forming
accessible regions for integration of foreign genetic mate-
rial. It is possible that viral DNA integration into actively
transcribed regions of cellular genome is a safety mecha-
nism to secure of viral genetic information.
Conclusions
Twelve human genomic sequences adjacent to integrated
HPV 16 DNA (HPV integration sites – INTs) expressed in
squamous cell cervical carcinomas have been character-
ised. A BLASTN homology search was performed for the
viral DNA integration sites and their surrounding se-
quences against the HGMT and EST databases. 11 INT
markers were found to be homologous human genomic
sequences and 9 of them had significant homologies to
known genes or ESTs. Locations of the 6 INTs were deter-
mined on the basis of the known locations of the corre-
sponding cDNAs. The RH-mapping technique has been
used to physically localise of five HPV INTs: INT254,
INT431 and INT407 (no homologies to genes or ESTs),
INT290 (homologies to two genomic sequences localised
on different chromosomes) and INT259 (short length of
homologous sequences).
The physical locations of five INT markers mapped by us
were in a good agreement with the locations of the corre-
sponding contigs of human genomic sequences. The loca-BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/24
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tions of these integration sites are also specific for each
tumour and all of the markers are present as a single copy
in one of the chromosomes including INT290 located on
Xp11.21. All of the INTs (mapped by us and localised us-
ing the data of genomic positions of homologous cDNAs)
are distributed in the regions with the high level of expres-
sion.
Integration of HPV genome occurs into the different hu-
man chromosomes but into the regions that contain high-
ly transcribed genes important for cell viability. One
possible interpretation of this phenomenon is that the re-
gions with actively transcribed genes are in extended chro-
matin configuration, forming accessible regions for
integration of foreign genetic material. It is also necessary
to point out that we analysed only expressed sequences
from integration sites in which cellular sequences local-
ised downstream to viral sequences. We cannot exclude
the possibility that after integration certain viral sequenc-
es become "silent" and this proposal has been confirmed
by Kiselev et al [3] and Van Tine et al [4].
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